1. Home
  2. TNXP vs LMNR Comparison

TNXP vs LMNR Comparison

Compare TNXP & LMNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$13.47

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Logo Limoneira Co

LMNR

Limoneira Co

HOLD

Current Price

$13.87

Market Cap

235.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
LMNR
Founded
2007
1893
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Farming/Seeds/Milling
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
199.7M
235.0M
IPO Year
2008
2005

Fundamental Metrics

Financial Performance
Metric
TNXP
LMNR
Price
$13.47
$13.87
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$20.00
AVG Volume (30 Days)
425.9K
56.2K
Earning Date
05-11-2026
06-08-2026
Dividend Yield
N/A
2.37%
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
$159,723,000.00
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
$13.95
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$9.40
$11.67
52 Week High
$34.00
$16.44

Technical Indicators

Market Signals
Indicator
TNXP
LMNR
Relative Strength Index (RSI) 59.03 60.92
Support Level $11.98 $13.87
Resistance Level $13.36 $14.21
Average True Range (ATR) 0.79 0.26
MACD 0.09 0.01
Stochastic Oscillator 60.55 68.00

Price Performance

Historical Comparison
TNXP
LMNR

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About LMNR Limoneira Co

Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.

Share on Social Networks: